Yuuwa Capital

Yuuwa Capital

Yuuwa Capital was founded in Perth in 2009 by Liddy McCall and James Williams to manage a $40 million venture capital fund seeded by the Australian Federal Government's Innovation Investment Fund program alongside private investors. Both co-founders came from operating careers — McCall as a Macquarie Bank M&A director turned startup founder, Williams as a biotech entrepreneur with five FDA-approved drugs and devices to his name — and they built the firm to replicate that hands-on approach across a concentrated life sciences portfolio. The firm targets early-stage life sciences ventures, covering seed, startup, and general venture stages within biotechnology, medical devices, and healthcare. Yuuwa operates as a specialist capital partner that provides both investment and operational expertise to scale companies. Its model relies on direct involvement from the co-founders, who hold board seats and executive roles at portfolio companies. Confirmed positions include ASX-listed AdAlta Limited, PolyActiva Pty Ltd, and Argenica Ltd. The geographic focus is anchored in Western Australia, with portfolio companies pursuing regulatory pathways in the United States and other global markets. Yuuwa operates with a lean team led by its two co-founders. McCall and Williams personally manage investments and governance, with McCall serving on boards including Argenica Ltd and the Ear Science Institute of Australia, and Williams chairing Dimerix Limited while directing PolyActiva. The firm has not disclosed a subsequent fund close beyond its 2009-vintage $40 million IIF vehicle. No additional offices or adjacent philanthropic structures are noted. Yuuwa's structure blurs the line between fund manager and operating company. Unlike a traditional venture firm that deploys investment professionals into passive board roles, both co-founders actively lead or chair portfolio companies, leveraging their own scientific and commercial track records. This dual operator-investor architecture is rare among Australian life sciences funds and reflects the firm's origin as a vehicle for its founders' direct company-building work.